British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK declared a third-quarter dividend of 15.00 pence per share, unchanged from the second quarter, but up 7.1% from 14.00p per share last year. It continues to expect a total dividend of 60.00p per ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...